Showing results (371-380 of 494) with videos related to
Sort By:
Pageof 50
Journal for Immunotherapy of Cancer|March 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trialDirk Schadendorf, Jason John Luke, Paolo A Ascierto, et al.Annals of Surgery|April 11, 2017
Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working GroupAndrea J MacNeill, Alessandro Gronchi, Rosalba Miceli, et al.Cancers|November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in EuropeMichael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.International Journal of Molecular Sciences|August 10, 2024
Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal Faecalibacillus intestinalis and Formic Acid as Commonly Altered in Cancer PatientsMaria Kulecka, Paweł Czarnowski, Aneta Bałabas, et al.Annals of Surgical Oncology|May 15, 2025
Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) CollaborationStijn J C van der Burg, Marco Fiore, Piotr Rutkowski, et al.The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.Journal for Immunotherapy of Cancer|December 28, 2020
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapyRoberta Turiello, Mariaelena Capone, Diana Giannarelli, et al.NEJM Evidence|February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced MelanomaGeorgina V Long, F Stephen Hodi, Evan J Lipson, et al.European Journal of Cancer (Oxford, England : 1990)|May 30, 2020
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialAlexander M M Eggermont, Piotr Rutkowski, Caroline Dutriaux, et al.Lancet (London, England)|March 9, 2026
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trialHairong Xu, Xiaohui Niu, Vinod Ravi, et al.Pageof 50